February 6, 2020 / 10:26 PM / 20 days ago

BRIEF-Collegium To Acquire U.S. Rights To Nucynta Franchise

Feb 6 (Reuters) - Collegium Pharmaceutical Inc:

* COLLEGIUM TO ACQUIRE U.S. RIGHTS TO NUCYNTA FRANCHISE

* COLLEGIUM PHARMACEUTICAL INC - DEAL FOR $375.0 MILLION IN CASH

* COLLEGIUM PHARMACEUTICAL INC - COLLEGIUM WILL ASSUME U.S. LICENSE FOR NUCYNTA FRANCHISE, AND WILL NO LONGER BE REQUIRED TO PAY ROYALTIES TO ASSERTIO.

* COLLEGIUM PHARMACEUTICAL INC - COLLEGIUM HAS SECURED DEBT FINANCING COMMITMENTS OF $325.0 MILLION

* COLLEGIUM PHARMACEUTICAL INC - COLLEGIUM WILL CONTINUE TO PAY GRUNENTHAL GMBH A FLAT 14% ROYALTY ON NET SALES OF NUCYNTA FRANCHISE

* COLLEGIUM PHARMACEUTICAL INC - COLLEGIUM WILL NO LONGER BE REQUIRED TO PAY A SUPPLEMENTAL ROYALTY ON SALES GREATER THAN $180.0 MILLION

* COLLEGIUM PHARMACEUTICAL - DEAL EXPECTED TO BE IMMEDIATELY ACCRETIVE AND TO SIGNIFICANTLY INCREASE COLLEGIUM’S PROFITABILITY AND OPERATING CASH FLOWS

* COLLEGIUM PHARMACEUTICAL INC - COLLEGIUM REITERATES ITS FULL-YEAR 2020 FINANCIAL GUIDANCE, INITIALLY PROVIDED ON JANUARY 7, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below